Covered recipient · General Payments record
JONATHAN A BERNSTEIN
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$64,236.66
114 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $47,457.78 | 22 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,325.34 | 34 |
| Food and Beverage | $1,278.18 | 53 |
| Travel and Lodging | $798.32 | 2 |
| Grant | $375.00 | 1 |
| Education | $2.04 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $16,571.57 | 8 |
| CSL Behring | $13,884.54 | 36 |
| Dermavant Sciences, Inc. | $7,320.00 | 3 |
| Eli Lilly and Company | $5,200.00 | 3 |
| BioCryst US Sales Co., LLC | $4,596.53 | 5 |
| AstraZeneca UK Limited | $3,821.83 | 3 |
| BioCryst Pharmaceuticals, Inc. | $3,300.00 | 2 |
| Merck Sharp & Dohme LLC | $2,790.00 | 2 |
| Regeneron Healthcare Solutions, Inc. | $1,671.96 | 2 |
| GlaxoSmithKline, LLC. | $1,469.69 | 19 |
| Celltrion USA Inc. | $750.00 | 1 |
| Celltrion, Inc. | $750.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $654.95 | 5 |
| Takeda Pharmaceuticals U.S.A., Inc. | $552.49 | 5 |
| BioMarin Pharmaceutical Inc. | $491.78 | 1 |
| PFIZER INC. | $143.87 | 8 |
| Blueprint Medicines Corporation | $125.70 | 2 |
| AbbVie Inc. | $70.99 | 4 |
| ALK-Abello, Inc | $23.41 | 1 |
| Amgen Inc. | $16.18 | 1 |
| GENZYME CORPORATION | $16.02 | 1 |
| LEO Pharma Inc. | $15.15 | 1 |
Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JONATHAN A BERNSTEIN
NPI 1093713638 · CMS profile ID 48714
Allopathic & Osteopathic Physicians / Allergy & Immunology
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1093713638?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JONATHAN A BERNSTEIN, NPI 1093713638, CMS profile ID 48714. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093713638?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JONATHAN A BERNSTEIN, NPI 1093713638, CMS profile ID 48714. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093713638?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JONATHAN A BERNSTEIN, NPI 1093713638, CMS profile ID 48714, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093713638?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
114 matching records · $64,236.66 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 114.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| CSL Behring | $117.13 | 07/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042880039 | CMS |
| CSL Behring | $93.70 | 07/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042880045 | CMS |
| AstraZeneca Pharmaceuticals LP | $537.00 | 07/12/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011424027 | CMS |
| BioCryst US Sales Co., LLC | $4,400.00 | 07/05/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012574047 | CMS |
| CSL Behring | $15.22 | 07/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042880023 | CMS |
| PFIZER INC. | $29.22 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050668957 | CMS |
| GlaxoSmithKline, LLC. | $10.15 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003190529 | CMS |
| GENZYME CORPORATION | $16.02 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049713273 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,375.00 | 06/21/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993423361 | CMS |
| CSL Behring | $799.20 | 06/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042880013 | CMS |
| PFIZER INC. | $24.34 | 06/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049289575 | CMS |
| Eli Lilly and Company | $2,400.00 | 06/02/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031595603 | CMS |
| CSL Behring | $79.47 | 05/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879993 | CMS |
| CSL Behring | $47.68 | 05/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879999 | CMS |
| CSL Behring | $38.15 | 05/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042880007 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $506.00 | 05/22/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055349125 | CMS |
| Regeneron Healthcare Solutions, Inc. | $49.46 | 05/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999095145 | CMS |
| CSL Behring | $711.22 | 05/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879985 | CMS |
| CSL Behring | $484.23 | 05/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879987 | CMS |
| LEO Pharma Inc. | $15.15 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053454183 | CMS |
| Merck Sharp & Dohme LLC | $697.50 | 04/26/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048546859 | CMS |
| AbbVie Inc. | $19.98 | 04/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996245903 | CMS |
| CSL Behring | $706.67 | 04/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879965 | CMS |
| CSL Behring | $481.13 | 04/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879971 | CMS |
| CSL Behring | $452.14 | 04/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879979 | CMS |
| GlaxoSmithKline, LLC. | $6.76 | 04/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003192393 | CMS |
| AbbVie Inc. | $20.52 | 04/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996245901 | CMS |
| Amgen Inc. | $16.18 | 04/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019973463 | CMS |
| BioCryst Pharmaceuticals, Inc. | $1,650.00 | 04/12/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012573789 | CMS |
| Blueprint Medicines Corporation | $16.34 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051255783 | CMS |
| GlaxoSmithKline, LLC. | $6.95 | 04/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003192377 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.88 | 03/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055349121 | CMS |
| CSL Behring | $1,625.00 | 03/25/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879961 | CMS |
| CSL Behring | $385.34 | 03/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879927 | CMS |
| CSL Behring | $273.67 | 03/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879933 | CMS |
| CSL Behring | $271.65 | 03/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879937 | CMS |
| CSL Behring | $776.94 | 03/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879943 | CMS |
| CSL Behring | $120.68 | 03/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879949 | CMS |
| CSL Behring | $528.31 | 03/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042879955 | CMS |
| AstraZeneca UK Limited | $3,759.00 | 03/23/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017032029 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.02 | 03/21/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055349117 | CMS |
| BioCryst US Sales Co., LLC | $100.42 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012573863 | CMS |
| GlaxoSmithKline, LLC. | $12.43 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003191451 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.57 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055349113 | CMS |
| GlaxoSmithKline, LLC. | $15.97 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003192381 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.02 | 03/07/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055349109 | CMS |
| GlaxoSmithKline, LLC. | $17.48 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1003193241 | CMS |
| Merck Sharp & Dohme LLC | $2,092.50 | 02/27/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048304323 | CMS |
| AstraZeneca UK Limited | $33.83 | 02/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016979603 | CMS |
| AstraZeneca UK Limited | $29.00 | 02/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017003485 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $20,089.18 | 6 |
| PY2025 | Principal investigator | $405,054.18 | 96 |
| PY2024 | Recipient | $24,796.06 | 12 |
| PY2024 | Principal investigator | $324,932.20 | 75 |
| PY2023 | Recipient | $16,377.63 | 10 |
| PY2023 | Principal investigator | $201,175.21 | 57 |
| PY2022 | Recipient | $16,846.00 | 3 |
| PY2022 | Principal investigator | $505,571.69 | 128 |
| PY2021 | Recipient | $8,808.00 | 8 |
| PY2021 | Principal investigator | $822,738.53 | 220 |
| PY2020 | Principal investigator | $475,283.95 | 113 |
| PY2019 | Recipient | $983.08 | 2 |
| PY2019 | Principal investigator | $988,525.04 | 109 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
102 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $11.31 | 12/30/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791986 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $47.87 | 12/30/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791990 |
| Principal investigator 1 | CSL Behring | $350.00 | 12/22/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673328 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $5,663.64 | 12/22/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791691 |
| Principal investigator 1 | CSL Behring | $1,592.00 | 12/15/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673326 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,710.63 | 12/12/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291527 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $47.98 | 12/10/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791328 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $6,889.68 | 12/10/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791332 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $8,011.60 | 12/10/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246791357 |
| Principal investigator 1 | CSL Behring | $350.00 | 12/03/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673324 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $700.53 | 11/24/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147684 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,030.00 | 11/24/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147689 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $32,784.84 | 11/21/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099266 |
| Principal investigator 1 | CSL Behring | $350.00 | 11/20/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673320 |
| Principal investigator 1 | CSL Behring | $2,184.00 | 11/20/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673322 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $927.00 | 11/20/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147669 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $525.00 | 11/20/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147674 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $165.00 | 11/19/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099276 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,856.00 | 11/19/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147665 |
| Principal investigator 1 | CSL Behring | $1,000.00 | 11/13/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673254 |
| Recipient | GENZYME CORPORATION | $500.00 | 11/07/2025 | Covered Recipient Physician | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 1226089163 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $47.78 | 11/05/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154625 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,496.70 | 10/28/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154642 |
| Principal investigator 1 | CSL Behring | $46.35 | 10/23/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673250 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,303.03 | 10/23/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099282 |
| Principal investigator 1 | CSL Behring | $4,002.00 | 10/22/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673318 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $46.35 | 10/17/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246789474 |
| Principal investigator 1 | CSL Behring | $3,996.00 | 10/14/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673248 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $4,053.98 | 10/14/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246789286 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $47.41 | 10/08/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154652 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $50,132.57 | 10/01/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190306475 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,467.50 | 10/01/2025 | Non-covered Recipient Entity University Of Cincinnati Physicians | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226098849 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,700.00 | 10/01/2025 | Non-covered Recipient Entity University Of Cincinnati Physicians | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226098854 |
| Principal investigator 1 | CSL Behring | $350.00 | 09/30/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673316 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18.12 | 09/25/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147693 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,466.39 | 09/24/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099288 |
| Principal investigator 1 | CSL Behring | $44.91 | 09/18/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673240 |
| Principal investigator 1 | CSL Behring | $3,604.00 | 09/15/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673314 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $4,057.86 | 09/15/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246787378 |
| Principal investigator 1 | CSL Behring | $300.00 | 09/11/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673238 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,222.10 | 09/10/2025 | Non-covered Recipient Entity University Of Cincinnati Physicians | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226098825 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $110.00 | 09/03/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099261 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,924.67 | 09/03/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147661 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,084.00 | 09/03/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192147679 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.39 | 08/26/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154638 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $42.37 | 08/25/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246786844 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $19,078.29 | 08/22/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154647 |
| Principal investigator 1 | CSL Behring | $42.37 | 08/19/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673234 |
| Principal investigator 1 | CSL Behring | $1,802.00 | 08/18/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673312 |
| Principal investigator 1 | CSL Behring | $228.32 | 08/14/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673054 |
| Principal investigator 1 | CSL Behring | $44.92 | 08/13/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673228 |
| Principal investigator 1 | CSL Behring | $50.00 | 08/13/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673230 |
| Principal investigator 1 | CSL Behring | $300.00 | 08/13/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673232 |
| Principal investigator 1 | CSL Behring | $8,694.00 | 08/12/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673226 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $7,512.56 | 08/07/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246786349 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,793.16 | 08/01/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192099270 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $986.00 | 08/01/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154629 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $110.00 | 08/01/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154655 |
| Principal investigator 1 | CSL Behring | $50.00 | 07/29/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673308 |
| Principal investigator 1 | CSL Behring | $350.00 | 07/29/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673310 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,408.75 | 07/25/2025 | Non-covered Recipient Entity University Of Cincinnati Physicians | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | No dispute reported | 06/30/2026 | 1226098836 |
| Principal investigator 1 | CSL Behring | $40.28 | 07/24/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673220 |
| Principal investigator 1 | CSL Behring | $300.00 | 07/24/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673222 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $32,850.18 | 07/18/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192154634 |
| Principal investigator 1 | CSL Behring | $1,870.00 | 07/14/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673306 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,384.64 | 07/14/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | IS744CS7 | No dispute reported | 06/30/2026 | 1246785251 |
| Principal investigator 1 | CSL Behring | $31.35 | 06/25/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673210 |
| Principal investigator 1 | CSL Behring | $300.00 | 06/25/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673212 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,242.00 | 06/25/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND | No dispute reported | 06/30/2026 | 1192158541 |
| Principal investigator 1 | CSL Behring | $150.00 | 06/24/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673206 |
| Principal investigator 1 | CSL Behring | $10,002.16 | 06/24/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673208 |
| Principal investigator 1 | CSL Behring | $350.00 | 06/20/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673304 |
| Principal investigator 1 | CSL Behring | $150.00 | 06/19/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673204 |
| Principal investigator 1 | CSL Behring | $1,870.00 | 06/09/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673302 |
| Principal investigator 1 | CSL Behring | $225.00 | 06/04/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673298 |
| Principal investigator 1 | CSL Behring | $350.00 | 06/04/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673300 |
| Principal investigator 1 | CSL Behring | $350.00 | 06/02/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673296 |
| Principal investigator 1 | CSL Behring | $5,714.00 | 05/30/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673294 |
| Recipient | F. Hoffmann-La Roche AG | $1,863.75 | 05/29/2025 | Covered Recipient Physician | A Phase III Trial of Xolair in CIU | No dispute reported | 06/30/2026 | 1211536797 |
| Principal investigator 1 | CSL Behring | $203.50 | 05/28/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673170 |
| Principal investigator 1 | CSL Behring | $12,040.00 | 05/28/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673202 |
| Principal investigator 1 | CSL Behring | $2,182.00 | 05/14/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673292 |
| Recipient | F. Hoffmann-La Roche AG | $3,666.67 | 05/09/2025 | Covered Recipient Physician | Omalizumab for People with Chronic Spontaneous Urticaria: Plain Language Summary of a Review | No dispute reported | 06/30/2026 | 1211536793 |
| Principal investigator 1 | CSL Behring | $350.00 | 04/28/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673290 |
| Principal investigator 1 | CSL Behring | $375.00 | 04/21/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673288 |
| Principal investigator 1 | CSL Behring | $1,904.00 | 04/11/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673286 |
| Recipient | F. Hoffmann-La Roche AG | $3,666.67 | 04/11/2025 | Covered Recipient Physician | Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial | No dispute reported | 06/30/2026 | 1211536790 |
| Principal investigator 1 | CSL Behring | $2,503.00 | 03/26/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age | No dispute reported | 06/30/2026 | 1252673158 |
| Principal investigator 1 | CSL Behring | $1,904.00 | 03/14/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673276 |
| Principal investigator 1 | CSL Behring | $4,364.00 | 03/12/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673274 |
| Principal investigator 1 | CSL Behring | $50.00 | 03/05/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673268 |
| Principal investigator 1 | CSL Behring | $300.00 | 03/05/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673270 |
| Principal investigator 1 | CSL Behring | $1,130.00 | 03/05/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673272 |
| Recipient | Novartis Pharmaceuticals Corporation | $7,681.46 | 02/27/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190292096 |
| Principal investigator 1 | CSL Behring | $1,904.00 | 02/19/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673266 |
| Principal investigator 1 | Amgen Inc. | $6,293.02 | 02/18/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1246639605 |
| Principal investigator 1 | CSL Behring | $226.72 | 02/05/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673050 |
| Principal investigator 1 | Amgen Inc. | $6,672.01 | 01/30/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | No dispute reported | 06/30/2026 | 1246639603 |
| Principal investigator 1 | CSL Behring | $364.28 | 01/27/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673186 |
| Principal investigator 1 | CSL Behring | $350.00 | 01/22/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age | No dispute reported | 06/30/2026 | 1252673264 |
| Principal investigator 1 | Amgen Inc. | $59,311.74 | 01/21/2025 | Non-covered Recipient Entity BERNSTEIN CLINICAL RESEARCH CENTER LLC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639599 |
| Principal investigator 1 | CSL Behring | $1,904.00 | 01/17/2025 | Non-covered Recipient Entity Bernstein Clinical Research Center | An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema | No dispute reported | 06/30/2026 | 1252673262 |